Search results for "Immunologic"

showing 10 items of 1115 documents

Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protect…

1999

Transcutaneous immunization (TCI) using ligands of Toll-like receptors (TLRs) and cytotoxic T-lymphocyte (CTL) epitopes lead to the induction of potent T-cell responses. To characterize the efficacy of TCI-mediated CTL activation, we monitored the frequency and functional activity of specific CTL induced with TCI using the ovalbumin-derived epitope SIINFEKL composed in creme containing the synthetic TLR7 ligand R-837. We found that the frequency and activity decayed rapidly 10 d post-TCI. Consistently, no significant memory T-cell formation was detectable. In a prophylactic vaccination setting, TCI was protective against a lethal challenge with ovalbumin expressing EG.7 thymoma cells when t…

Time Factorsmedicine.drug_classT cellmedicine.medical_treatmentBiologyMonoclonal antibodyAdministration CutaneousLymphocyte ActivationEpitopeMiceAntigenCell Line TumorNeoplasmsmedicineImmunology and AllergyCytotoxic T cellAnimalsCD40 AntigensImiquimodGeneral MedicineImmunotherapyMice Inbred C57BLSurvival RateCTL*medicine.anatomical_structureImmunizationImmunologyAminoquinolinesImmunizationImmunotherapyImmunologic MemoryNeoplasm TransplantationT-Lymphocytes CytotoxicClinical reviews in allergyimmunology
researchProduct

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.

1997

Abstract The current study was carried out to elucidate the immunoregulatory changes induced by venom immunotherapy (VIT) in bee or wasp allergic subjects. All subjects included in this study had a history of severe systemic allergic reactions to stings of the respective insect as well as positive skin tests with the respective venom or venom-specific IgE in the sera. Parameters assessed in peripheral blood mononuclear cells (PBMC) before and after initiation of VIT (rush therapy reaching a maintenance dose of 100 micrograms venom injected subcutaneously within 1 week) were expression of CD3, CD4, CD8, CD45RA, CD45RO, interleukin (IL)-2 receptor (R) alpha, IL-4R, IL-12R, Fc epsilon RII, CD4…

Time Factorsmedicine.medical_treatmentImmunologyCD40 LigandDown-RegulationVenomWasp VenomsImmunoglobulin ELigandsLymphocyte ActivationPeripheral blood mononuclear cellInterferon-gammaTh2 CellsAntigens CDT-Lymphocyte SubsetsmedicineImmunology and AllergyHumansLymphocyte CountRNA MessengerCD40 AntigensCD40Membrane GlycoproteinsbiologyReceptors IgEInterleukinAntibodies MonoclonalInsect Bites and StingsReceptors InterleukinAllergensTh1 CellsInterleukin-10Receptors Interleukin-4Interleukin 10Bee VenomsCytokineDesensitization ImmunologicImmunologyAntigens Surfacebiology.proteinInterleukin-4AntibodyEuropean journal of immunology
researchProduct

Prostaglandin E(2)-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release.

2008

PGE(2), an arachidonic acid metabolite produced by various type of cells regulates a broad range of physiological activities in the endocrine, cardiovascular, gastrointestinal, and immune systems, and is involved in maintaining the local homeostasis. In the immune system, PGE(2) is mainly produced by APCs and it can suppress the Th1-mediated immune responses. The aim of this study was to develop PGE(2)-loaded biodegradable MS that prolong and sustain the in vivo release of this mediator. An o/w emulsion solvent extraction-evaporation method was chosen to prepare the MS. We determined their diameters, evaluated the in vitro release of PGE(2), using enzyme immunoassay and MS uptake by periton…

Time Factorsmedicine.medical_treatmentPhagocytosisChemistry PharmaceuticalDrug CompoundingPharmaceutical ScienceInflammationPharmacologyBiologyNitric OxideDinoprostonechemistry.chemical_compoundMiceImmune systemPhagocytosisIn vivoSepsismedicineAnimalsHumansImmunologic FactorsProstaglandin E2Particle SizeCells CulturedChemokine CCL2Tumor Necrosis Factor-alphaEndothelial CellsWaterGeneral MedicineMicrospheresDisease Models AnimalchemistryBiochemistrySolubilityDelayed-Action PreparationsMacrophages PeritonealLiberationlipids (amino acids peptides and proteins)Arachidonic acidEmulsionsmedicine.symptomInflammation MediatorsOilsBiotechnologyProstaglandin Emedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

2010

The potent anti-tumour activities of gamma delta T cells have prompted the development of protocols in which gamma delta-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a V gamma 9V delta 2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of V gamma 9V delta 2 T …

Translational Studiesmedicine.medical_treatmentLymphocyte ActivationZoledronic AcidMetastasisTNF-Related Apoptosis-Inducing LigandProstate cancerT-Lymphocyte SubsetsImmunology and AllergyMedicineDiphosphonatesRemission InductionEsterasesImidazolesReceptors Antigen T-Cell gamma-deltaMiddle AgedMetastatic breast cancerTreatment Outcomemedicine.anatomical_structureDisease ProgressionCytokinesFemaleImmunotherapyBreast diseaseChemokinesT cellImmunologyBreast NeoplasmsInterferon-gammaHemiterpenesOrganophosphorus CompoundsBreast cancerAdjuvants ImmunologicVgamma9Vdelta2 T cells Zoledronate interleukin-2advanced breast cancer patientsHumansLymphocyte CountAgedCell ProliferationSalvage Therapybusiness.industryLysineMucin-1CancerImmunotherapymedicine.diseaseTumor Necrosis Factor Receptor Superfamily Member 7ImmunologyInterleukin-2Leukocyte Common Antigensbusiness
researchProduct

CC chemokine receptor 5Δ32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation

2004

Ischemic-type biliary lesions are a major complication following orthotopic liver transplantation. They occur in up to 26% of liver transplant recipients. Among other factors, unknown immunologic factors have always been assumed to be partly responsible for these lesions. CC-chemokines and their receptors play a key role in postoperative immunomodulation after liver transplantation. The non-function CC-chemokine receptor 5Δ32 polymorphism (CCR5Δ32) has been shown to lead to a lower rate of acute rejection after kidney transplantation; in liver transplantation the role of CCR5Δ32 is unclear. We investigated the influence of the CCR5Δ32 after liver transplantation with special regard to ische…

TransplantationPathologymedicine.medical_specialtyHepatologyOrthotopic liver transplantationImmunologic Factorsbusiness.industrymedicine.medical_treatmentHeterozygote advantageLiver transplantationmedicine.diseaseGastroenterologyInternal medicinemedicineSurgeryMajor complicationReceptorbusinessCC chemokine receptorsKidney transplantationLiver Transplantation
researchProduct

Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease

2021

Subjects with immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis (RA), have an intrinsic higher probability to develop active-tuberculosis (TB) compared to the general population. The risk ranges from 2.0 to 8.9 in RA patients not receiving therapies. According to the WHO, the RA prevalence varies between 0.3% and 1% and is more common in women and in developed countries. Therefore, the identification and treatment of TB infection (TBI) in this fragile population is important to propose the TB preventive therapy. We aimed to study the M. tuberculosis (Mtb) specific T-cell response to find immune biomarkers of Mtb burden or Mtb clearance in patients with different TB …

TuberculosisImmunologyPopulationchemical and pharmacologic phenomenaDiseaseMycobacterium tuberculosisImmune systemmedicineM. tuberculosisImmunology and AllergyCytotoxic T celleducationIFN-γCD27Original Researcheducation.field_of_studybiologybusiness.industryRC581-607bacterial infections and mycosesmedicine.diseasebiology.organism_classificationtuberculosisRheumatoid arthritisImmunologyTumor necrosis factor alphaImmunologic diseases. Allergybusinessimmune-mediated inflammatory disease
researchProduct

Plasmacytoid dendritic cells are inefficient in activation of human regulatory T cells

2011

BACKGROUND: Dendritic cells (DC) play a key role in initiation and regulation of immune responses. Plasmacytoid DC (pDC), a small subset of DC, characterized as type-I interferon producing cells, are critically involved in anti-viral immune responses, but also mediate tolerance by induction of regulatory T cells (Treg). In this study, we compared the capacity of human pDC and conventional DC (cDC) to modulate T cell activity in presence of Foxp3(+) Treg. PRINCIPAL FINDINGS: In coculture of T effector cells (Teff) and Treg, activated cDC overcome Treg anergy, abrogate their suppressive function and induce Teff proliferation. In contrast, pDC do not break Treg anergy but induce Teff prolifera…

Tumor ImmunologyT cellImmune CellsImmunology610 Medizinlcsh:MedicineAntigen-Presenting Cellschemical and pharmacologic phenomenaAutoimmunityBiologyLymphocyte ActivationT-Lymphocytes RegulatoryFlow cytometryImmunomodulationImmune systemInterferonNeutralization Tests610 Medical sciencesmedicineCytotoxic T cellHumanslcsh:ScienceBiologyImmune ResponseCell ProliferationMultidisciplinarymedicine.diagnostic_testCell growthT Cellslcsh:RFOXP3hemic and immune systemsForkhead Transcription FactorsDendritic CellsImmunologic SubspecialtiesCoculture TechniquesCell biologymedicine.anatomical_structureLymphocyte activationCytokinesMedicinelcsh:QClinical ImmunologyInflammation Mediatorsmedicine.drugResearch Article
researchProduct

Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response

2021

During tumor growth, angiogenesis is required to ensure oxygen and nutrient transport to the tumor. Vascular endothelial growth factor (VEGF) is the major inducer of angiogenesis and appears to be a key modulator of the anti-tumor immune response. Indeed, VEGF modulates innate and adaptive immune responses through direct interactions and indirectly by modulating protein expressions on endothelial cells or vascular permeability. The inhibition of the VEGF signaling pathway is clinically approved for the treatment of several cancers. Therapies targeting VEGF can modulate the tumor vasculature and the immune response. In this review, we discuss the roles of VEGF in the anti-tumor immune respon…

Vascular Endothelial Growth Factor AAngiogenesisAngiogenesis InhibitorsVascular permeabilityReviewAdaptive Immunityimmune responsechemistry.chemical_compoundangiogenesisNeoplasmsVEGF Signaling PathwayInducerBiology (General)SpectroscopyNeovascularization Pathologicvascular endothelial growth factorGeneral MedicineSorafenibComputer Science ApplicationsBevacizumabGene Expression Regulation NeoplasticVascular endothelial growth factorVascular endothelial growth factor AChemistrySignal TransductionQH301-705.5Recombinant Fusion ProteinsAntibodies Monoclonal HumanizedCatalysisCapillary PermeabilityInorganic ChemistryImmune systemmedicineHumansImmunologic FactorscancerPhysical and Theoretical ChemistryMolecular BiologyQD1-999Vascular Endothelial Growth Factor Receptor-1business.industryOrganic ChemistryEndothelial CellsCancermedicine.diseaseImmunity InnateReceptors Vascular Endothelial Growth FactorchemistryCancer researchbusinessInternational Journal of Molecular Sciences
researchProduct

Ovine Carotid Artery-Derived Cells as an Optimized Supportive Cell Layer in 2-D Capillary Network Assays

2014

PLoS one 9(3), e91664 (2014). doi:10.1371/journal.pone.0091664

Vascular Endothelial Growth Factor APathologyCellBecaplerminlcsh:MedicineCardiovascularUmbilical veinUmbilical CordDrug DiscoveryMolecular Cell BiologyBiological Systems EngineeringMyocyteCardiovascular Imaginglcsh:ScienceMultidisciplinaryProto-Oncogene Proteins c-sisAnimal ModelsFlow CytometryEndothelial stem cellBevacizumabmedicine.anatomical_structureCarotid ArteriesMonoclonalMedicineImmunohistochemical AnalysisResearch ArticleBiotechnologymedicine.medical_specialtyCell typeDrugs and DevicesDrug Research and DevelopmentMyocytes Smooth MuscleImmunologyBiomedical EngineeringBioengineeringBiologyAntibodies Monoclonal HumanizedCell LineModel OrganismsVascular Biologymedicine.arterymedicineAnimalsHumansBiologySheeplcsh:REndothelial CellsFeeder CellsUmbilical arteryMolecular biologyVascular Endothelial Growth Factor Receptor-2Coculture TechniquesCapillariesCell cultureImmunologic Techniqueslcsh:QCytometry
researchProduct

On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety.

1995

Combined treatment with trypsin, cholesterol esterase, and neuraminidase transforms LDL, but not HDL or VLDL, to particles with properties akin to those of lipid extracted from atherosclerotic lesions. Single or double enzyme modifications, or treatment with phospholipase C, or simple vortexing are ineffective. Triple enzyme treatment disrupts the ordered and uniform structure of LDL particles, and gives rise to the formation of inhomogeneous lipid droplets 10-200 nm in diameter with a pronounced net negative charge, but lacking significant amounts of oxidized lipid. Enzymatically modified LDL (E-LDL), but not oxidatively modified LDL (ox-LDL), is endowed with potent complement-activating c…

Very low-density lipoproteinArteriosclerosisImmunologyNeuraminidaseComplement Membrane Attack Complexchemistry.chemical_compoundLipid dropletmedicineExtracellularImmunology and AllergyHumansTrypsinReceptors ImmunologicComplement ActivationGlycoproteinsReceptors Lipoproteinchemistry.chemical_classificationReceptors ScavengerPhospholipase CCholesterolMacrophagesMembrane ProteinsComplement C3Complement System ProteinsArticlesScavenger Receptors Class BSterol EsteraseTrypsinLipid MetabolismLipoproteins LDLEnzymechemistryBiochemistryLow-density lipoproteinlipids (amino acids peptides and proteins)medicine.drugFoam CellsThe Journal of experimental medicine
researchProduct